['psoriasis']
['idp-118 vehicle lotion', 'idp-118 vehicle cream', 'idp-118 lotion', 'ultravate cream']

        Key Inclusion Criteria:

          -  Male or female, of any race, at least 18 years of age (inclusive).

          -  Freely provides both verbal and written informed consent.

          -  Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA
             (Body Surface Area) of at least 3%, but no more than 12%. The face, scalp, palms,
             soles, axillae, and intertriginous areas are to be excluded in this calculation.

          -  Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet
             radiation (natural and artificial) for the duration of the study.

          -  Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA (Investigators
             Global Assessment) score of 3 or 4. (The face, scalp, palms, soles, axillae, and
             intertriginous areas are to be excluded in this assessment, if psoriasis is present.)

          -  If female and of childbearing potential, must have a negative urine and serum
             pregnancy test at the Screening visit and negative urine pregnancy at Baseline visit
             prior to randomization.

          -  Subject is willing to comply with study instructions and return to the clinic for
             required visits.

        Key Exclusion Criteria:

          -  Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular
             psoriasis, as determined by the investigator.

          -  Presents with psoriasis that was treated with prescription medication and failed to
             respond to treatment, even partially or temporarily, as determined by the
             investigator.

          -  Presents with any concurrent skin condition that could interfere with the evaluation
             of the treatment areas, as determined by the investigator.

          -  Is pregnant, nursing an infant, or planning a pregnancy during the study period.

          -  Has received treatment with any investigational drug or device within 60 days or 5
             drug half-lives (whichever is longer) prior to the Baseline visit, or is concurrently
             participating in another clinical study with an investigational drug or device.
      